Lv11
32 积分 2024-09-09 加入
A randomized, placebo‐controlled, single and multiple dose study of intravenous thymosin β4 in healthy volunteers
1小时前
待确认
Liraglutide in Acute Minor Ischemic Stroke or High-Risk Transient Ischemic Attack With Type 2 Diabetes
13天前
已完结
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
13天前
已完结
Kardiovaskuläre Auswirkungen einer Liraglutidtherapie bei Patienten mit Typ-2-Diabetes
13天前
已完结
Orforglipron ( LY3502970 ), a novel, oral non‐peptide glucagon‐like peptide‐1 receptor agonist: A Phase 1b, multicentre, blinded, placebo‐controlled, randomized, multiple‐ascending‐dose study in people with type 2 diabetes
1个月前
已完结
Orforglipron ( LY3502970 ), a novel, oral non‐peptide glucagon‐like peptide‐1 receptor agonist: A Phase 1a, blinded, placebo‐controlled, randomized, single‐ and multiple‐ascending‐dose study in healthy participants
1个月前
已完结
Disposition and Absolute Bioavailability of Orally Administered Orforglipron in Healthy Participants
1个月前
已完结
Pharmacokinetic Bioequivalence of Orforglipron Tablets and Capsules in Healthy Participants With Obesity or Overweight
1个月前
已完结
Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity
3个月前
已完结
An Assessment of Concerns Regarding New Regulatory Guidance for Combination Products: A Review of the Submissions Made to the FDA Regarding Their Proposed Draft New Guidance on Human Factors Studies for a Combination Product in an Abbreviated New Drug Application
4个月前
已完结
皖公网安备34019202002308
